Standards message here

Lymphoma and Multiple Myeloma

Multiple Myeloma

1

Disease Status and/or Stage Relapsed or refractory
Protocol Title A Phase II Study of VEGF Trap for the Treatment of Relapsed or Refractory Multiple Myeloma
PI Ruben Niesvizky, MD
Contact

Mary Crann, RN
212-746-1480
Or visit: MyelomaCenter.org

Key Eligibility

For patients with stage IIa or IIIa multiple myeloma with measurable disease defined by serum M protein greater than or equal to 1.0 gm/dl measured by serum protein electrophoresis or free light chain measurement of more than 200 mg/dl and/or urinary M protein excretion greater than or equal to 200 mg/24 hours.

Patients must have had 2 or fewer prior therapies.

Patient must have normal organ and marrow function.

Treatment Overview

Patients will receive a dose of VEGF Trap by infusion on Day 1 of each 14 day cycle. Patients can receive VEGF Trap until they experience progression of disease or unacceptable adverse events.

2

Disease Status and/or Stage Relapsed or Refractory Multiple Myeloma
Protocol Title Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 In Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma
PI Ruben Niesvizky, MD
Contact

Mary Crann, RN
212-746-1480
Or visit: MyelomaCenter.org

Key Eligibility Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies. All previous therapies for cancer must be discontinued for at least 4 weeks (2 weeks for lenalidomide or thalidomide) before study entry.
Treatment Overview

PD 0332991 will be given orally, starting on Day 1 of each cycle, once a day for 3 weeks (21 days) followed by one week (7 days) without treatment. Bortezomib and dexamethasone will be administered on Days 8, 11, 15, and 18 of Cycles 1 through 10. One cycle is defined as 4 weeks (28 days). The maximum treatment period will be 10 cycles or 280 days.

3

Disease Status and/or Stage Progressive Disease after therapies with curative potential or approved salvage regimen.
Protocol Title Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1
PI Ellen Chung , M.D.
Contact Kristen Petrillo, R.N.
212-746-5430

 

 
Last updated: January 5, 2011
© Weill Medical College of Cornell University
Home | Privacy Notice | Disclaimer